StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Dawson James began coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a “buy” rating and a $3.00 target price on the stock.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock opened at $0.17 on Friday. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.31. The company has a quick ratio of 1.81, a current ratio of 2.53 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $0.28 and a 200 day simple moving average of $0.38. The company has a market cap of $14.24 million, a P/E ratio of -0.02 and a beta of 2.21.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.95 million. On average, sell-side analysts forecast that Tonix Pharmaceuticals will post -3.71 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals accounts for 0.5% of Sabby Management LLC’s investment portfolio, making the stock its 6th largest position. Sabby Management LLC owned about 7.02% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.